Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Dow Jones Today: Stock Indexes Jump to Begin Holiday-Shortened Trading Week; Nasdaq, S&P 500 Soar
02:30pm, Monday, 24'th Nov 2025
Major stock indexes jumped Monday to begin a holiday-shortened trading week, with investors increasingly confident the Federal Reserve will cut interest rates at its December meeting.
Eli Lilly is better at executing now than Novo Nordisk, says BMO's Evan Seigerman
02:12pm, Monday, 24'th Nov 2025
Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, the valuation gap between the stocks and much more.
Top Stock Movers Now: Alphabet, Tesla, Carvana, Novo Nordisk, and More
12:41pm, Monday, 24'th Nov 2025
Major U.S. equities indexes climbed Monday afternoon as tech stocks rallied, and as optimism about a rate cut by the Federal Reserve next month grew. The Dow rose 0.4% and the S&P 500 added 1.3%, whil
Citi's Geoff Meacham: Novo misses on Alzheimer's trial, but ‘winners keep winning' in obesity drugs
12:31pm, Monday, 24'th Nov 2025
Geoff Meacham, Citi head of U.S. pharma and biotech research, joins CNBC's 'Money Movers' to discuss his reaction to results from a drug trial Novo Nordisk, outlooks on the stock, and much more.
Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.
12:25pm, Monday, 24'th Nov 2025
Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.
Novo Nordisk's Alzheimer's Trials Disappoint, Impacting Stock Performance
11:14am, Monday, 24'th Nov 2025
Novo Nordisk (NVO) shares are dropping after the company announced that its Phase 3 EVOKE and EVOKE+ trials of oral semaglutide failed to show a statistically s
Novo Nordisk shares slide after semaglutide Alzheimer's trial misses primary goal
11:13am, Monday, 24'th Nov 2025
Shares of Novo Nordisk (NYSE:NVO) fell sharply on Monday after the Danish pharmaceutical giant said a late-stage trial testing its diabetes and weight-loss drug semaglutide in Alzheimer's disease did
Novo Nordisk 'lottery ticket' Alzheimer's trials fail to deliver reward
11:02am, Monday, 24'th Nov 2025
Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it can slow the disease's progression - were always a long-shot, although they had offered the drugmaker a potential
Failing Drug Stock Suffers Another Blow on Drug Trial Data
10:46am, Monday, 24'th Nov 2025
Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's dru
Novo Nordisk stock slides as its Alzheimer's drug trials fail
10:21am, Monday, 24'th Nov 2025
Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to
Novo Nordisk: Semaglutide's Success In Alzheimer's Was Unlikely
10:20am, Monday, 24'th Nov 2025
Novo Nordisk shares dropped after oral semaglutide failed in phase 3 Alzheimer's trials, ending hopes for this indication. The level of supportive evidence prior to this trial's readout was not high a
Ozempic-maker's shares plunge after failed Alzheimer's trial
09:32am, Monday, 24'th Nov 2025
Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer's disease.
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
09:31am, Monday, 24'th Nov 2025
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
5 Things to Know Before the Stock Market Opens
08:35am, Monday, 24'th Nov 2025
Stock futures are pointing to a higher open for major indexes to kick off the holiday-shortened trading week; market participants are growing increasingly confident that the Federal Reserve will cut i
Holiday air travel, Novo Nordisk trial results, 'Wicked: For Good' debut and more in Morning Squawk
08:21am, Monday, 24'th Nov 2025
Stocks are coming off a losing week, though a Friday rally mitigated declines. U.S. airlines are expecting another record Thanksgiving travel period.
